The deal, financial terms of which were not disclosed, will see PharmPoint and MRCS provide “the basic resources necessary to conduct” Phase I trials of the agent in the treatment of drug resistant cancers.
Earlier this year contract manufacturing organisation (CMO) Formatech won selected by Cellceutix to supply stocks of Kevetrin as a lyophilised powder for reconstitution in saline solution for Phase I studies.
Preclinical testing of the drug was also outsourced , with US contract research organisation (CRO) Toxikon completing final development of the drug late last year.